Articles by Tyler Menichiello

  1. Exciting Areas Of Innovation For Cell Therapies 12/23/2024

    In this segment of the executive roundtable discussion, our panelists express optimism about the promising future of allogeneic cell therapies and discuss other innovations in the field.

  2. Leveraging Directed Evolution To Optimize AAV Vector Design 12/18/2024

    4D Molecular Therapeutics (4DMT) CEO and co-founder, David Kirn, MD, talks about the company’s approach to vector optimization, its product development, and its stage-appropriate buildup of internal GMP manufacturing.

  3. Developing Bespoke Antisense Oligonucleotides To Treat Rare Diseases 11/26/2024

    EveryONE Medicines CEO, Kent Rogers, explains the company’s mission to address a major unmet need in children with rare neurodegenerative diseases, one patient at a time.

  4. Allogene's Mission To Democratize CAR-T 11/22/2024

    Allogene Therapeutics CEO and co-founder, David Chang, MD, Ph.D., talks about the exciting future of allogeneic CAR-T and shares the company's mission to bring these therapies to patients.

  5. Regeneron's Strategy To Address Congenital Deafness 10/30/2024

    Regeneron's Jonathon Whitton, Au.D., Ph.D., and Christos Kyratsous, Ph.D., discuss the company's clinical and developmental strategy for DB-OTO, a gene therapy to treat congenital deafness.

  6. Tune Therapeutics On Clinical Readiness, Technology Adoption 10/16/2024

    Heidi Zhang, Ph.D., explains Tune Therapeutics' epigenetic approach to gene therapy and how the company is preparing its lead candidate for the clinic, as well as it's modular approach to automation.

  7. How Platform Technologies Are Shaping The Gene Therapy Landscape 9/30/2024

    Leading experts in gene therapy discuss CMC strategy for platform technologies, product lifecycle management, and the role CDMOs play in moving the space forward.

  8. Gene Therapy CMC Experts On Late-Stage Process Changes 9/27/2024

    At the 2024 Bioprocessing Summit, a panel of CMC experts spoke about the challenges commercializing gene therapies, specifically focusing on considerations for late-stage process changes.

  9. The Future Of Autologous CAR-T Manufacturing: Balancing Innovation With Improvement 9/12/2024

    Experts from last month's Cell & Gene Live event discuss the innovations seen in CAR-T manufacturing and shared their thoughts on the feasibility of decentralized and point-of-care models to address manufacturing challenges.

  10. Key Takeaways From The 2024 Bioprocessing Summit 8/26/2024

    Editor Tyler Menichiello reflects on the topics and trends covered at this year's Bioprocessing Summit in Boston.